Serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate and changes in levels following robotic-assisted laparoscopic radical prostatectomy

Turk J Med Sci. 2020 Dec 17;50(8):1872-1878. doi: 10.3906/sag-2004-353.

Abstract

Background/aim: This study aimed to examine serum paraoxonase 1 and 3 (PON1 and PON3) activities in benign and malignant diseases of the prostate, to determine lipid profile and malondialdehyde (MDA) levels, and to investigate changes in levels following robotic-assisted laparoscopic radical prostatectomy (RALRP).

Materials and methods: A total of 137 patients, including a control group, were enrolled in the study and assigned into four groups. Group 1 (n = 33) consisted of patients previously undergoing RALRP with no recurrence, group 2 (n = 36) consisted of patients diagnosed with prostate cancer (PCa) and undergoing RALRP, and group 3 (n = 34) consisted of patients diagnosed with benign prostatic hyperplasia. The control group (n = 34) consisted of healthy individuals. Serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, cholesterol, prostate-specific antigen (PSA), PON1, PON3, and MDA values were measured. In addition, group 2 MDA, PON1, PON3, and PON1/HDL levels were investigated preoperatively and at the first month postoperatively.

Results: Significant changes were found in PON1, PON3, and MDA levels. PON1 and PON3 levels decreased significantly in patients with PCa, while MDA levels increased. PON1 and PON3 increased postoperatively in the PCa group, while MDA decreased. BPH group PON1, PON3, and MDA levels were higher than those of the control group.

Conclusion: An increase in free oxygen radicals in the body or a decrease in endogenous antioxidant enzyme levels can result in malignant and benign diseases of the prostate. Surgical excision of malignant tissue in PCa causes a decrease in oxidative stress.

Keywords: Paraoxonase 1; benign prostatic hyperplasia; malondialdehyde; paraoxonase 3; prostate cancer.

MeSH terms

  • Aged
  • Aryldialkylphosphatase / blood*
  • Aryldialkylphosphatase / genetics
  • Humans
  • Laparoscopy / methods*
  • Male
  • Malondialdehyde / blood
  • Middle Aged
  • Prostate / surgery
  • Prostatectomy / methods*
  • Prostatic Diseases / blood*
  • Prostatic Diseases / genetics
  • Prostatic Diseases / surgery*
  • Robotic Surgical Procedures / methods*

Substances

  • Malondialdehyde
  • Aryldialkylphosphatase
  • PON1 protein, human
  • PON3 protein, human